Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States. Sera Prognostics Update
Monday, September 25, 2023 BiopharmaWatch Research 1 min read
Key Takeaway: Sera Prognostics has announced a collaboration with Elevance to improve maternal and neonatal health through the PreTRM identification method. This collaboration involves a multicenter prospective randomized controlled study with up to 6,500 participants across approximately 15 U.S. sites. The primary outcomes will focus on reducing hospital lengths of stay and neonatal morbidity and mortality, creating valuable data for future clinical applications of PreTRM.
Price reaction · baseline $1.75 (2023-09-22 close) · clean, no other SERA news in the window
day 0 close
+1.7%
day 1
+9.7%
day 3
+9.1%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration with Elevance aims to enhance maternal and neonatal health.
The study evaluates the benefit of PreTRM for identifying high-risk pregnancies.
Data collected can serve as a template for future clinical uses of PreTRM.
Full Press Release Details
Collaboration with Elevance based on health economic analysis from HealthCore Multicenter prospective randomized controlled study within Elevance network Up to 6,500 participants in approx. 15 U.S. sites Evaluates benefit of PreTRM identification of higher risk pregnancies coupled with proactive interventions Primary outcomes are hospital length of stay and neonatal morbidity / mortality Builds data that can be a template for future clinical use of PreTRM PRIME Study: Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs Elevance Health (formerly Anthem) and Sera Collaborate to Improve Maternal and Neonatal Health
Frequently Asked Questions
What is the Elevance study about?
The Elevance study evaluates the benefits of PreTRM identification for high-risk pregnancies.
How many participants are involved in the study?
Up to 6,500 participants are participating across approximately 15 U.S. sites.
What are the primary outcomes of the study?
The primary outcomes include hospital length of stay and neonatal morbidity/mortality.
What does the PreTRM PRIME study focus on?
It focuses on prematurity risk assessment combined with clinical interventions.
Who are the collaborators in this study?
Elevance Health and Sera are collaborating to improve maternal and neonatal health.